Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3 Active not recruiting 939 enrolled Celgene Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Timeline

Start: 2022-06-23
Primary completion: 2027-11-16
Completion: 2032-06-25

Publications

Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Comparator	Daratumumab	Monoclonal antibody	1800 mg	Subcutaneous
Comparator	Dexamethasone	Small molecule	20 mg	Oral
Comparator	Dexamethasone	Small molecule	40 mg	Oral
Subject	Iberdomide	Small molecule	1 mg	Oral
Subject	Iberdomide	Small molecule	1.3 mg	Oral
Subject	Iberdomide	Small molecule	1.6 mg	Oral

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

Timeline

Publications

Drugs

Indications